Company Entia Biosciences, Inc.

Equities

ERGO

US29384E1047

Biotechnology & Medical Research

Market Closed - OTC Markets 11:08:36 2024-04-26 am EDT 5-day change 1st Jan Change
0.0001 USD -.--% Intraday chart for Entia Biosciences, Inc. -.--% -.--%

Business Summary

Entia Biosciences, Inc. develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Company also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The Company's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The Company's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.

Number of employees: 7

Sales per Business

USD in Million2015Weight2016Weight Delta
Dietary Supplements, Nutraceuticals and Medical Foods Products
100.0 %
0 100.0 % 0 100.0 % -23.48%

Sales per region

USD in Million2015Weight2016Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -23.48%

Managers

Managers TitleAgeSince
Chief Executive Officer 67 15-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,660,947 33,660,947 ( 100.00 %) 0 99.44 %
Stock B 0 188,563 0 0

Shareholders

NameEquities%Valuation
14,625 9.720 % 29 $

Company contact information

Entia Biosciences, Inc.

13565 SW Tualatin-Sherwood Road Suite 800

97140, Sherwood

+

http://www.entiabio.com
address Entia Biosciences, Inc.(ERGO)
  1. Stock Market
  2. Equities
  3. ERGO Stock
  4. Company Entia Biosciences, Inc.